NL-OMON38640已完成不适用
eural basis of cognitive control symptoms in schizophrenia - Cognitive control in schizophrenia
niversitair Medisch Centrum Utrecht0 个研究点目标入组 90 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 12 至 99（—）
入选标准
- •1) Must be between the ages of 18-55
- •2) Schizophrenia patients: must have a diagnosis of schizophrenia or schizoaffective disorder
- •3) Schizophrenia patients: must be stablized on psychotropic medications
- •4) Healthy first-degree relative: must have a first-degree relative with schizophrenia or schizoaffective disorder
- •5) Be mentally competent, as determined by their treating physician.
- •6) Provide written informed consent.
排除标准
- •1) Non-removable metal objects in head/body
- •2) pregnancy
- •3) history of closed or open head injury with loss of consciousness
- •4) personal history of psychiatric illness (in healthy first-degree relatives and healthy non-relatives)
- •5) history of neurological illness
- •6) use of psychotropic medications in healthy controls and relatives
- •7) substance abuse or dependence within the preceding 6 months (except nicotine)
- •8) claustrophobia
- •9) history of schizophrenia in first-degree family members of healthy non-relative controls
研究者
相似试验
招募中
不适用
Intra-cortical Inhibition and Cognitive Deficits in SchizophreniaSchizophreniaNCT05542212Tongji University200
已完成
不适用
The interaction of Cognitive Control Mechanisms and Language Processing: An Investigation with MethylphenidateCognitive and attention disorders and disturbancesexecutive functionreadingNL-OMON48291Radboud Universiteit Nijmegen40
进行中（未招募）
1 期
Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus TolcaponTOCTAP (Treatment of Cognitive Deficits in Schizophrenia with Tolcapone and Pergolide) - TOCTAPDas vorliegende Projektvorhaben dient der Untersuchung, inwieweit bei Patienten mit schizophrenen Störungen neben einer bestehenden Monotherapie mit Paliperidon (Invega), dem zuletzt zugelassenen neuartigen Antipsychotikum der sog. zweiten Generation, eine additive prodopaminerge Psychopharmakotherapie mit Tolcapon (Tasmar) oder Pergolid (Parkotil) die präfrontalen kognitiven Funktionen beeinflusst.EUCTR2008-006905-18-DERWTH Aachen University60
已完成
不适用
Controllability of cognitive brain signals and the effects on the frontostriatal network: A 7T fMRI study.The research is fundamental in nature and only healthy subjects are studied. The knowledge that will be gained could eventually be used for medical interventions (e.g. new treatment methods for psychiatric disorders). Furthermore, the results are interesting for those who are developing brain-computer interfaces.NL-OMON40199niversitair Medisch Centrum Utrecht30
已完成
不适用
ature and mechanisms of cognitive deficits following chemotherapy: an (f)MRI studycognitive deficitsmemory and concentration problems10009841NL-OMON34510Antoni van Leeuwenhoek Ziekenhuis180